INmune Bio Inc.
$1.49
▼
-1.63%
2026-04-21 07:31:01
www.inmunebio.com
NCM: INMB
Explore INmune Bio Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$39.61 M
Current Price
$1.49
52W High / Low
$11.64 / $1.09
Stock P/E
—
Book Value
$0.89
Dividend Yield
—
ROCE
-128.97%
ROE
-1.65%
Face Value
—
EPS
$-1.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
0.89
Debt / Equity
4.4
Current Ratio
3.55
Quick Ratio
3.55
Forward P/E
-1.51
Price / Sales
627.41
Enterprise Value
$7.65 M
EV / EBITDA
-0.25
EV / Revenue
153.07
Rating
Strong Buy
Target Price
$7
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 2. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 3. | Ligand Pharmaceuticals Incorporated | $231.78 | 36.85 | $4.59 B | — | 3.1% | 13.47% | $238.31 / $98.89 | $51.44 |
| 4. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
| 5. | Instil Bio, Inc. | $8.39 | — | $56.9 M | — | -26.15% | -50.39% | $42.79 / $5.67 | $16.79 |
| 6. | Sana Biotechnology, Inc. | $3.82 | — | $939.37 M | — | -60.83% | -1.19% | $6.55 / $1.53 | $0.6 |
| 7. | MapLight Therapeutics, Inc. | $28.34 | — | $1.28 B | — | -36.5% | -56.19% | $31.13 / $12.24 | $10.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.05 M | 0 M | — |
| Operating Profit | -5.47 M | -7.43 M | -8.06 M | -9.9 M | -9.47 M | — |
| Net Profit | -5.26 M | -6.47 M | -24.46 M | -9.74 M | -9.22 M | — |
| EPS in Rs | -0.2 | -0.24 | -0.92 | -0.37 | -0.35 | -0.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.05 M | 0.01 M | 0.15 M | 0.37 M |
| Operating Profit | -30.87 M | -42.63 M | -29.74 M | -25.95 M |
| Net Profit | -45.93 M | -42.08 M | -30.01 M | -27.3 M |
| EPS in Rs | -1.73 | -1.58 | -1.13 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 32.35 M | 39.56 M | 57 M | 81.8 M |
| Total Liabilities | 8.83 M | 7.46 M | 18.86 M | 21.69 M |
| Equity | 23.52 M | 32.1 M | 38.14 M | 60.1 M |
| Current Assets | 29.89 M | 22.66 M | 39.94 M | 64.67 M |
| Current Liabilities | 8.42 M | 7.22 M | 18.46 M | 10.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.58 M | -33.36 M | -11.98 M | -22.69 M |
| Investing CF | -1.04 M | 0 M | — | 0 M |
| Financing CF | 27.61 M | 18.21 M | -4.22 M | 0.73 M |
| Free CF | -23.62 M | -33.36 M | -11.98 M | -22.69 M |
| Capex | -1.04 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -90.97% | -58.56% | — | — |
| Earnings Growth % | -40.24% | -9.92% | — | — |
| Profit Margin % | -300585.71% | -19360% | -7299.2% | — |
| Operating Margin % | -304535.71% | -19187.74% | -6938.77% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -304535.71% | -19187.74% | -6938.77% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.